Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability and Food Effect Study of BMS-986435 Tablet Formulations in Healthy Adults
NCT07226817Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BMS-986435 in hypertrophic cardiomyopathy (HCM) (12 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed concentration, Area under the concentration-time curve from time zero to time of last quantifiable concentration and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
BMS-986435
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT07226817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226817.